Yoshikatsu Kanai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1497849/publications.pdf

Version: 2024-02-01

		26567	17055	
150	15,566	56	122	
papers	citations	h-index	g-index	
154	154	154	11739	

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Primary structure and functional characterization of a high-affinity glutamate transporter. Nature, 1992, 360, 467-471.	13.7	1,276
2	Molecular identification of a renal urate–anion exchanger that regulates blood urate levels. Nature, 2002, 417, 447-452.	13.7	1,270
3	Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98). Journal of Biological Chemistry, 1998, 273, 23629-23632.	1.6	945
4	Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature, 1994, 368, 563-566.	13.7	838
5	Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1514, 291-302.	1.4	604
6	CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Archiv European Journal of Physiology, 2004, 447, 532-542.	1.3	587
7	Expression Cloning and Characterization of a Novel Multispecific Organic Anion Transporter. Journal of Biological Chemistry, 1997, 272, 18526-18529.	1.6	553
8	The SLC3 and SLC7 families of amino acid transporters. Molecular Aspects of Medicine, 2013, 34, 139-158.	2.7	516
9	Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity. Journal of Biological Chemistry, 1999, 274, 19745-19751.	1.6	443
10	Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. Molecular Pharmacology, 2002, 61, 729-737.	1.0	361
11	Amino acid transporters revisited: New views in health and disease. Trends in Biochemical Sciences, 2018, 43, 752-789.	3.7	308
12	Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder. Cell, 2016, 167, 1481-1494.e18.	13.5	265
13	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Molecular Aspects of Medicine, 2013, 34, 108-120.	2.7	255
14	The 4F2hc/LAT1 complex transports I-DOPA across the blood–brain barrier. Brain Research, 2000, 879, 115-121.	1.1	253
15	<scp> </scp> â€Type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Science, 2010, 101, 173-179.	1.7	216
16	Expression Cloning of a Na+-independent Aromatic Amino Acid Transporter with Structural Similarity to H+/Monocarboxylate Transporters. Journal of Biological Chemistry, 2001, 276, 17221-17228.	1.6	211
17	L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. International Journal of Cancer, 2006, 119 , $484-492$.	2.3	211
18	Lâ€ŧype aminoâ€acid transporter 1 as a novel biomarker for highâ€grade malignancy in prostate cancer. Pathology International, 2009, 59, 7-18.	0.6	204

#	Article	IF	CITATIONS
19	Identification of a Novel System L Amino Acid Transporter Structurally Distinct from Heterodimeric Amino Acid Transporters. Journal of Biological Chemistry, 2003, 278, 43838-43845.	1.6	203
20	Organic Anion Transporter Family: Current Knowledge. Journal of Pharmacological Sciences, 2006, 100, 411-426.	1.1	186
21	Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat Kidney. Journal of Biological Chemistry, 1995, 270, 29365-29371.	1.6	176
22	Identification of an Amino Acid Transporter Associated with the Cystinuria-related Type II Membrane Glycoprotein. Journal of Biological Chemistry, 1999, 274, 28845-28848.	1.6	158
23	Correlation of Lâ€type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Science, 2012, 103, 382-389.	1.7	152
24	Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. Journal of Physiology, 2013, 591, 609-625.	1.3	152
25	Maternal Protein Restriction in the Rat Inhibits Placental Insulin, mTOR, and STAT3 Signaling and Down-Regulates Placental Amino Acid Transporters. Endocrinology, 2011, 152, 1119-1129.	1.4	146
26	Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Annals of the Rheumatic Diseases, 2016, 75, 652-659.	0.5	144
27	The ancillary proteins of HATs: SLC3 family of amino acid transporters. Pflugers Archiv European Journal of Physiology, 2004, 447, 490-494.	1.3	140
28	Heterodimeric Amino Acid Transporters: Molecular Biology and Pathological and Pharmacological Relevance. Current Drug Metabolism, 2001, 2, 339-354.	0.7	133
29	Expression of a system L neutral amino acid transporter at the blood–brain barrier. NeuroReport, 2000, 11, 3507-3511.	0.6	128
30	Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1565, 112-122.	1.4	127
31	<scp> </scp> â€type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Science, 2008, 99, 2380-2386.	1.7	126
32	Transport of 3-Fluoro-l-α-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET. Journal of Nuclear Medicine, 2012, 53, 1253-1261.	2.8	120
33	ENHANCED TUMOR GROWTH ELICITED BY L-TYPE AMINO ACID TRANSPORTER 1 IN HUMAN MALIGNANT GLIOMA CELLS. Neurosurgery, 2008, 62, 493-504.	0.6	118
34	BCH, an Inhibitor of System L Amino Acid Transporters, Induces Apoptosis in Cancer Cells. Biological and Pharmaceutical Bulletin, 2008, 31, 1096-1100.	0.6	115
35	Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nature Structural and Molecular Biology, 2019, 26, 510-517.	3.6	110
36	Boronophenylalanine, a boron delivery agent forÂboron neutron capture therapy, is transported byÂ <scp>ATB</scp> ^{0,+} , <scp>LAT</scp> 1 and <scp>LAT</scp> 2. Cancer Science, 2015, 106, 279-286.	1.7	109

3

#	Article	IF	CITATIONS
37	Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study. Clinical Cancer Research, 2007, 13, 6369-6378.	3.2	99
38	Increased placental nutrient transport in a novel mouse model of maternal obesity with fetal overgrowth. Obesity, 2015, 23, 1663-1670.	1.5	95
39	Slc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells. Cell Reports, 2017, 21, 1824-1838.	2.9	95
40	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Research, 2010, 30, 4819-28.	0.5	95
41	Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer, 2013, 13, 482.	1.1	81
42	Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics., 2022, 230, 107964.		78
43	Regulation of amino acid transporter trafficking by mTORC1Âin primary human trophoblast cells is mediated by the ubiquitin ligase Nedd4-2. Clinical Science, 2016, 130, 499-512.	1.8	76
44	Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 775-780.	3.3	72
45	Identification and Characterization of a Novel Member of the Heterodimeric Amino Acid Transporter Family Presumed to be Associated with an Unknown Heavy Chain. Journal of Biological Chemistry, 2001, 276, 49390-49399.	1.6	69
46	Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 681-690.	1.4	68
47	Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With ^ ^alpha;-Alkyl Moieties. Journal of Pharmacological Sciences, 2012, 119, 368-380.	1.1	67
48	The small SLC43 family: Facilitator system I amino acid transporters and the orphan EEG1. Molecular Aspects of Medicine, 2013, 34, 638-645.	2.7	66
49	CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases. Annals of Surgical Oncology, 2009, 16, 3473-3481.	0.7	65
50	Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer, 2009, 66, 120-126.	0.9	65
51	Identification of a Novel Na+-independent Acidic Amino Acid Transporter with Structural Similarity to the Member of a Heterodimeric Amino Acid Transporter Family Associated with Unknown Heavy Chains. Journal of Biological Chemistry, 2002, 277, 21017-21026.	1.6	63
52	Establishment and Characterization of Mammalian Cell Lines Stably Expressing Human L-Type Amino Acid Transporters. Journal of Pharmacological Sciences, 2008, 108, 505-516.	1.1	63
53	JPH203, an L-Type Amino Acid Transporter 1–Selective Compound, Induces Apoptosis of YD-38 Human Oral Cancer Cells. Journal of Pharmacological Sciences, 2014, 124, 208-217.	1.1	62
54	Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation. Biochemical Journal, 2001, 358, 693-704.	1.7	60

#	Article	IF	CITATIONS
55	System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Letters, 2009, 276, 95-101.	3.2	60
56	Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). Journal of Pharmacological Sciences, 2017, 133, 96-102.	1.1	60
57	Expression and functional characterisation of System L amino acid transporters in the human term placenta. Reproductive Biology and Endocrinology, 2015, 13, 57.	1.4	59
58	Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 94-102.	1.3	58
59	Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells. Journal of Urology, 2016, 195, 1588-1597.	0.2	57
60	18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 321-331.	3.3	56
61	Expression of Lâ€type amino acid transporter 1 (<scp>LAT</scp> 1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Science, 2014, 105, 1496-1502.	1.7	54
62	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathology Research and Practice, 2008, 204, 553-561.	1.0	53
63	Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflugers Archiv European Journal of Physiology, 2020, 472, 1177-1206.	1.3	53
64	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Research, 2015, 25, 399-405.	0.6	52
65	Expression of amino acid transporters (<scp>LAT1</scp> , <scp>ASCT2</scp> and <scp>xCT</scp>) as clinical significance in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1014-1022.	1.8	51
66	Structure–activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling. Amino Acids, 2016, 48, 1045-1058.	1.2	51
67	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. American Journal of Translational Research (discontinued), 2011, 3, 468-78.	0.0	51
68	Lâ€type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I nonâ€small cell lung cancer. Histopathology, 2009, 54, 804-813.	1.6	49
69	Lysophosphatidylcholine Enhances Cytokine Production of Endothelial Cells via Induction of L-Type Amino Acid Transporter 1 and Cell Surface Antigen 4F2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1640-1645.	1.1	48
70	¹⁸ F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2009, 50, 1770-1776.	2.8	47
71	Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals. Scientific Reports, 2015, 5, 15057.	1.6	47
72	Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 141-153.	1.1	45

#	Article	IF	Citations
73	CYP450s-Activity Relations of Celastrol to Interact with Triptolide Reveal the Reasons of Hepatotoxicity of Tripterygium wilfordii. Molecules, 2019, 24, 2162.	1.7	45
74	L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer. Molecular and Clinical Oncology, 2013, 1, 274-280.	0.4	44
75	Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precusor lesions. Anticancer Research, 2004, 24, 1671-5.	0.5	44
76	Essential Roles of L-Type Amino Acid Transporter 1 in Syncytiotrophoblast Development by Presenting Fusogenic 4F2hc. Molecular and Cellular Biology, 2017, 37, .	1.1	43
77	Efficacy of system <scp>l</scp> amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Science, 2016, 107, 1499-1505.	1.7	40
78	Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Archives of Pharmacal Research, 2005, 28, 421-432.	2.7	39
79	Protein Characterization of Na+-Independent System L Amino Acid Transporter 3 in Mice. American Journal of Pathology, 2007, 170, 888-898.	1.9	39
80	<scp>L</scp> â€type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. Journal of Surgical Oncology, 2009, 99, 433-438.	0.8	39
81	Impairment of the carnitine/organic cation transporter 1–ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease. Kidney International, 2017, 92, 1356-1369.	2.6	39
82	Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1692-1700.	3.3	38
83	Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2016, 113, 381-389.	0.8	38
84	Evaluation of thoracic tumors with ¹⁸ Fâ€FMT and ¹⁸ Fâ€FDG PETâ€CT: A clinicopathological study. International Journal of Cancer, 2009, 124, 1152-1160.	2.3	36
85	Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation. Journal of Experimental and Clinical Cancer Research, 2020, 39, 266.	3.5	36
86	The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Research, 2006, 26, 2943-8.	0.5	36
87	Specific transport of 3â€fluoroâ€ <scp> </scp> â€Î±â€methylâ€tyrosine by <scp>LAT</scp> 1 explains its specificity malignant tumors in imaging. Cancer Science, 2016, 107, 347-352.	y <u>†.</u> 9	35
88	Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Scientific Reports, 2020, 10, 1292.	1.6	35
89	Amino Acid Transporter LAT3 Is Required for Podocyte Development and Function. Journal of the American Society of Nephrology: JASN, 2009, 20, 1586-1596.	3.0	34
90	Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma. Pathology and Oncology Research, 2015, 21, 1175-1181.	0.9	34

#	Article	IF	Citations
91	Ratiometric fluorescence imaging of cell surface pH by poly(ethylene glycol)-phospholipid conjugated with fluorescein isothiocyanate. Scientific Reports, 2017, 7, 17484.	1.6	34
92	Molecular architecture of the stria vascularis membrane transport system, which is essential for physiological functions of the mammalian cochlea. European Journal of Neuroscience, 2015, 42, 1984-2002.	1.2	33
93	αâ€Emitting cancer therapy using ²¹¹ Atâ€AAMT targeting LAT1. Cancer Science, 2021, 112, 1132-2	11 .4 0.	31
94	Localization of the high-affinity glutamate transporter EAAC1 in rat kidney. American Journal of Physiology - Renal Physiology, 1997, 273, F1023-F1029.	1.3	30
95	Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice. Oncotarget, 2020, 11, 1388-1398.	0.8	30
96	Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Translational Oncology, 2021, 14, 100915.	1.7	27
97	Expression and functional characterization of the system I amino acid transporter in KB human oral epidermoid carcinoma cells. Cancer Letters, 2004, 205, 215-226.	3.2	26
98	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Human Pathology, 2019, 84, 142-149.	1.1	26
99	Inhibition of L-Type Amino Acid Transporter Modulates the Expression of Cell Cycle Regulatory Factors in KB Oral Cancer Cells. Biological and Pharmaceutical Bulletin, 2010, 33, 1117-1121.	0.6	25
100	Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. American Journal of Translational Research (discontinued), 2015, 7, 1126-39.	0.0	23
101	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. American Journal of Translational Research (discontinued), 2015, 7, 1161-71.	0.0	23
102	CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma. Head and Neck, 2015, 37, 1569-1574.	0.9	22
103	Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. Anticancer Research, 2019, 39, 2535-2543.	0.5	21
104	Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter. Journal of Pharmacological Sciences, 2019, 139, 215-222.	1.1	21
105	A novel role of the C-terminus of b0,+AT in the ER–Golgi trafficking of the rBAT–b0,+AT heterodimeric amino acid transporter. Biochemical Journal, 2009, 417, 441-448.	1.7	20
106	Development of a Widely Usable Amino Acid Tracer: ⁷⁶ Br-α-Methyl-Phenylalanine for Tumor PET Imaging. Journal of Nuclear Medicine, 2015, 56, 791-797.	2.8	20
107	Simple But Efficacious Enrichment of Integral Membrane Proteins and Their Interactions for In-Depth Membrane Proteomics. Molecular and Cellular Proteomics, 2022, 21, 100206.	2.5	20
108	Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model. EJNMMI Physics, 2021, 8, 4.	1.3	19

#	Article	IF	Citations
109	Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor. Cancer Science, 2021, 112, 3871-3883.	1.7	19
110	Linkage of N-cadherin to multiple cytoskeletal elements revealed by a proteomic approach in hippocampal neurons. Neurochemistry International, 2012, 61, 240-250.	1.9	18
111	Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma. Pathology and Oncology Research, 2013, 19, 649-656.	0.9	16
112	LAT1â€specific inhibitor is effective against T cellâ€mediated allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 463-467.	2.7	16
113	Transport of 3-fluoro-l-α-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [18F]FAMT positron emission tomography. Journal of Pharmacological Sciences, 2016, 130, 101-109.	1.1	15
114	Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor. Cancer Science, 2021, 112, 871-883.	1.7	15
115	Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. American Journal of Translational Research (discontinued), 2015, 7, 356-63.	0.0	15
116	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Scientific Reports, 2022, 12, 2742.	1.6	13
117	Gene expression profiles in t24 human bladder carcinoma cells by inhibiting an l-type amino acid transporter, lat1. Archives of Pharmacal Research, 2007, 30, 444-452.	2.7	12
118	A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy. PLoS ONE, 2020, 15, e0241869.	1.1	12
119	NRFL-1, the C. elegans NHERF Orthologue, Interacts with Amino Acid Transporter 6 (AAT-6) for Age-Dependent Maintenance of AAT-6 on the Membrane. PLoS ONE, 2012, 7, e43050.	1.1	11
120	Expression of a human NPT1/SLC17A1 missense variant which increases urate export. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 536-542.	0.4	11
121	Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex. PLoS Biology, 2018, 16, e2005090.	2.6	11
122	Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2. Annals of Nuclear Medicine, 2019, 33, 394-403.	1.2	10
123	Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer. Anticancer Research, 2017, 37, 631-636.	0.5	9
124	Clinical Significance and Phenotype of MTA1 Expression in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2017, 37, 4147-4155.	0.5	9
125	Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans. Pharmaceutical Research, 2017, 34, 1233-1243.	1.7	8
126	Characterization of amino acid transport system L in HTB-41 human salivary gland epidermoid carcinoma cells. Anticancer Research, 2008, 28, 2649-55.	0.5	8

#	Article	IF	CITATIONS
127	Significance of System L Amino Acid Transporter 1 (LAT-1) and 4F2 Heavy Chain (4F2hc) Expression in Human Developing Intestines. Acta Histochemica Et Cytochemica, 2009, 42, 73-81.	0.8	7
128	Interaction of Halogenated Tyrosine/Phenylalanine Derivatives with Organic Anion Transporter 1 in the Renal Handling of Tumor Imaging Probes. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 451-462.	1.3	7
129	Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In Vivo, 2021, 35, 2425-2432.	0.6	6
130	Developing selective L-Amino Acid Transport 1 (LAT1) inhibitors: A Structure-Activity Relationship overview. Medical Research Archives, $2019, 7, .$	0.1	4
131	Ultrastructural immunohistochemical study of L-type amino acid transporter 1–4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma. Journal of Electron Microscopy, 2017, 66, 198-203.	0.9	3
132	Structural changes induced by ligand binding drastically increase the thermostability of the Ser/Thr protein kinase TpkD from ThermusÂthermophilus HB8. FEBS Letters, 2021, 595, 264-274.	1.3	3
133	Tmem174, a regulator of phosphate transporter prevents hyperphosphatemia. Scientific Reports, 2022, 12, 6353.	1.6	3
134	Functional coupling of organic anion transporter OAT10 (SLC22A13) and monocarboxylate transporter MCT1 (SLC16A1) influencing the transport function of OAT10. Journal of Pharmacological Sciences, 2022, , .	1.1	3
135	Evaluation of D-isomer of F-FBPA for oncology PET focusing on the differentiation of glioma and inflammation. Asia Oceania Journal of Nuclear Medicine and Biology, 2020, 8, 102-108.	0.1	2
136	Expression of Amino Acid Transporters in Cancers and Their Application to Cancer Diagnosis and Therapuitics. Membrane, 2008, 33, 108-117.	0.0	1
137	Studies on the Incompatibility between Bulbus fritillariae and Radix aconiti praeparata Based on the P-gp. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11.	0.5	O
138	Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in tongue cancer Journal of Clinical Oncology, 2015, 33, e22204-e22204.	0.8	0
139	Comprehensive protein analysis of the transport system in a connective tissue of the inner ear. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-145.	0.0	O
140	Phosphoproteome analysis reveals novel cellular responses affect by inhibition of LAT1, a cancer type amino acid transporter. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-46.	0.0	0
141	Structure activity relations of aromatic amino acid derivatives to interact with organic anion transporter OAT1 reveal critical moieties for renal accumulation of tumor imaging probes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-8-40.	0.0	0
142	L-type amino acid transporter 1 (LAT1) in endothelial cells of tumor vessels contributes to tumor angiogenesis. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-30.	0.0	0
143	BPA-dipeptides, novel boron delivery agents for boron neutron capture therapy, are transported by oligopeptide transporter. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-32.	0.0	0
144	Combination of amino acids necessary and sufficient for the optimal activation of mTORC1. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-6-13.	0.0	0

#	Article	IF	CITATIONS
145	Development of anti-tumor drugs targeting amino acid transporters in cancers. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, JKG-02.	0.0	O
146	Comparative phosphoproteomics between non-competitive and competitive inhibitions of L-type amino acid transporter 1 in cancer cells Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, 1-P-106.	0.0	0
147	Title is missing!. , 2020, 15, e0241869.		O
148	Title is missing!. , 2020, 15, e0241869.		0
149	Title is missing!. , 2020, 15, e0241869.		O
150	Title is missing!. , 2020, 15, e0241869.		0